|
[1]
|
Perfect, J.R. (2017) The Antifungal Pipeline: A Reality Check. Nature Reviews Drug Discovery, 16, 603-616. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Denning, D.W. (2024) Global Incidence and Mortality of Severe Fungal Disease. The Lancet Infectious Diseases, 24, e428-e438. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Kupferschmidt, K. (2019) New Drugs Target Growing Threat of Fatal Fungi. Science, 366, 407. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Anderson, T.M., Clay, M.C., Cioffi, A.G., Diaz, K.A., Hisao, G.S., Tuttle, M.D., et al. (2014) Amphotericin Forms an Extramembranous and Fungicidal Sterol Sponge. Nature Chemical Biology, 10, 400-406. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Belenky, P., Camacho, D. and Collins, J.J. (2013) Fungicidal Drugs Induce a Common Oxidative-Damage Cellular Death Pathway. Cell Reports, 3, 350-358. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Hamilton-Miller, J.M. (1973) Chemistry and Biology of the Polyene Macrolide Antibiotics. Bacteriological Reviews, 37, 166-196. [Google Scholar] [CrossRef]
|
|
[7]
|
Lewandowska, A., Soutar, C.P., Greenwood, A.I., Nimerovsky, E., De Lio, A.M., Holler, J.T., et al. (2021) Fungicidal Amphotericin B Sponges Are Assemblies of Staggered Asymmetric Homodimers Encasing Large Void Volumes. Nature Structural & Molecular Biology, 28, 972-981. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Loo, A.S., Muhsin, S.A. and Walsh, T.J. (2013) Toxicokinetic and Mechanistic Basis for the Safety and Tolerability of Liposomal Amphotericin B. Expert Opinion on Drug Safety, 12, 881-895. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Faustino, C. and Pinheiro, L. (2020) Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics, 12, Article 29. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Aguilar-Zapata, D., Petraitiene, R. and Petraitis, V. (2015) Echinocandins: The Expanding Antifungal Armamentarium. Clinical Infectious Diseases, 61, S604-S611. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Denning, D.W. (2003) Echinocandin Antifungal Drugs. The Lancet, 362, 1142-1151. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Alexander, B.D., Johnson, M.D., Pfeiffer, C.D., Jiménez-Ortigosa, C., Catania, J., Booker, R., et al. (2013) Increasing Echinocandin Resistance in Candida Glabrata: Clinical Failure Correlates with Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations. Clinical Infectious Diseases, 56, 1724-1732. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Salem, H., Ahmed, S.M. and Omar, M.M. (2016) Liposomal Flucytosine Capped with Gold Nanoparticle Formulations for Improved Ocular delivery. Drug Design, Development and Therapy, 10, 277-295. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Fang, X., Li, D., Tangadanchu, V.K.R., Gopala, L., Gao, W. and Zhou, C. (2017) Novel Potentially Antifungal Hybrids of 5-Flucytosine and Fluconazole: Design, Synthesis and Bioactive Evaluation. Bioorganic & Medicinal Chemistry Letters, 27, 4964-4969. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Allen, D., Wilson, D., Drew, R. and Perfect, J. (2015) Azole Antifungals: 35 Years of Invasive Fungal Infection Management. Expert Review of Anti-infective Therapy, 13, 787-798. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Fainstein, V. and Bodey, G.P. (1980) Cardiorespiratory Toxicity Due to Miconazole. Annals of Internal Medicine, 93, 432-433. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Khanna, D. and Bharti, S. (2014) Luliconazole for the Treatment of Fungal Infections: An Evidence-Based Review. Core Evidence, 9, 113-124. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Cha, R. and Sobel, J.D. (2004) Fluconazole for the Treatment of Candidiasis: 15 Years Experience. Expert Review of Anti-infective Therapy, 2, 357-366. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Troke, P.F., Andrews, R.J., Pye, G.W. and Richardson, K. (1990) Fluconazole and Other Azoles: Translation of in Vitro Activity to in Vivo and Clinical Efficacy. Clinical Infectious Diseases, 12, S276-S280. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Anaissie, E.J., Darouiche, R.O., Abi-Said, D., Uzun, O., Mera, J., Gentry, L.O., et al. (1996) Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole versus Amphotericin B and Review of the Literature. Clinical Infectious Diseases, 23, 964-972. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Dolton, M.J. and McLachlan, A.J. (2014) Optimizing Azole Antifungal Therapy in the Prophylaxis and Treatment of Fungal Infections. Current Opinion in Infectious Diseases, 27, 493-500. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Pound, M.W., Townsend, M.L., Dimondi, V., Wilson, D. and Drew, R.H. (2011) Overview of Treatment Options for Invasive Fungal Infections. Medical Mycology, 49, 561-580. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Lass-Flörl, C. (2011) Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review. Drugs, 71, 2405-2419. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chapman, S.W., Dismukes, W.E., Proia, L.A., Bradsher, R.W., Pappas, P.G., Threlkeld, M.G., et al. (2008) Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 46, 1801-1812. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Stevens, D.A. (1997) Analysis of Compassionate Use Itraconazole Therapy for Invasive Aspergillosis by the NIAID Mycoses Study Group Criteria. Archives of Internal Medicine, 157, 1857-1862. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Johnson, L.B. and Kauffman, C.A. (2003) Voriconazole: A New Triazole Antifungal Agent. Clinical Infectious Diseases, 36, 630-637. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Sabatelli, F., Patel, R., Mann, P.A., Mendrick, C.A., Norris, C.C., Hare, R., et al. (2006) In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts. Antimicrobial Agents and Chemotherapy, 50, 2009-2015. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Raad, I.I., Graybill, J.R., Bustamante, A.B., Cornely, O.A., Gaona-Flores, V., Afif, C., et al. (2006) Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections. Clinical Infectious Diseases, 42, 1726-1734. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Leber, R., Fuchsbichler, S., Klobučníková, V., Schweighofer, N., Pitters, E., Wohlfarter, K., et al. (2003) Molecular Mechanism of Terbinafine Resistance in Saccharomycescerevisiae. Antimicrobial Agents and Chemotherapy, 47, 3890-3900. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Thompson III, G.R., Soriano, A., Cornely, O.A., et al. (2023) Rezafungin versus Caspofungin for Treatment of Candidaemia and Invasive Candidiasis (ReSTORE): A Multicentre, Double-Blind, Double-Dummy, Randomised Phase 3 Trial. Lancet, 401, 49-59.
|
|
[31]
|
Soriano, A., Honore, P.M., Cornely, O.A., Chayakulkeeree, M., Bassetti, M., Haihui, H., et al. (2024) Treatment Outcomes among Patients with a Positivecandidaculture Close to Randomization Receiving Rezafungin or Caspofungin in the Restore Study. Clinical Infectious Diseases, 79, 672-681. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Maertens, J.A., Thompson III, G.R., Spec, A,. et al. (2025) Olorofim for the Treatment of Invasive Fungal Diseases in Patients with Few or No Therapeutic Options: A Single-Arm, Open-Label, Phase 2b Study. The Lancet Infectious Diseases, 25, 1177-1188.
|
|
[33]
|
Georgacopoulos, O., Nunnally, N., Ransom, E., Law, D., Birch, M., Lockhart, S., et al. (2021) In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents. Journal of Fungi, 7, Article 378. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Gebremariam, T., Alkhazraji, S., Gu, Y., Singh, S., Alqarihi, A., Shaw, K.J., et al. (2019) Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and Chemotherapy, 64, e01966-19. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Gebremariam, T., Alkhazraji, S., Alqarihi, A., Wiederhold, N.P., Shaw, K.J., Patterson, T.F., et al. (2020) Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus Arrhizus. Antimicrobial Agents and Chemotherapy, 64, e00178-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Pappas, P.G., Vazquez, J.A., Oren, I., Rahav, G., Aoun, M., Bulpa, P., et al. (2023) Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, for the Treatment of Candidaemia: Results from a Phase 2 Trial. Journal of Antimicrobial Chemotherapy, 78, 2471-2480. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Vazquez, J.A., Pappas, P.G., Boffard, K., Paruk, F., Bien, P.A., Tawadrous, M., et al. (2023) Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida Auris: Results from a Phase 2 Trial. Antimicrobial Agents and Chemotherapy, 67, e01419-22. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Spec, A., Pullman, J., Thompson, G.R., Powderly, W.G., Tobin, E.H., Vazquez, J., et al. (2019) MSG-10: A Phase 2 Study of Oral Ibrexafungerp (SCY-078) Following Initial Echinocandin Therapy in Non-Neutropenic Patients with Invasive Candidiasis. Journal of Antimicrobial Chemotherapy, 74, 3056-3062. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Schwebke, J.R., Sobel, R., Gersten, J.K., Sussman, S.A., Lederman, S.N., Jacobs, M.A., et al. (2021) Ibrexafungerp versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clinical Infectious Diseases, 74, 1979-1985. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Deng, Q., Li, Y., He, W., Chen, T., Liu, N., Ma, L., et al. (2025) A Polyene Macrolide Targeting Phospholipids in the Fungal Cell Membrane. Nature, 640, 743-751. [Google Scholar] [CrossRef] [PubMed]
|